The Big Questions to Drive Action Campaign


Just as the 2000 International AIDS Conference in Durban served as a catalyst for global treatment advocacy and access, the return of the conference to Durban this year will be a defining moment to establish a clear path toward guaranteeing that no one is left behind in the AIDS response.

Each International AIDS Conference has served as a landmark moment in the HIV response. Now we must define the legacy of the 21st International AIDS Conference (AIDS 2016). As we make our way towards the road to Durban and beyond, we have gone out and asked experts some of the essential questions that we must address at AIDS 2016. Through the Big Questions to Drive Action campaign, we’ll be sharing key insights from experts and leaders to help provide a clearer direction for a path forward.

Join us and share your answers to some of the guiding questions! Take a photo or a video of yourself answering one of the Big Questions to Drive Action listed below, and share it to Facebook, Twitter, and Instagram using #AIDS2016.


Questions to drive action


  • How can we ensure that frontline workers have easy access to the latest evidence and the ability to implement it?
  • How can access to HIV prevention, care and treatment be seamlessly integrated with other priority health issues, including sexual and reproductive health and other comorbidities including tuberculosis, malaria and hepatitis?
  • What are we doing to move the latest World Health Organization treatment guidelines from goal to reality?
  • Whose responsibility is it to ensure countries have what they need to expand access to treatment? How can we scale up differentiated models of HIV treatment delivery?
  • What role should the private sector and workplace play in “getting to zero”?
  • What are national governments and donors doing to ensure comprehensive prevention is well-funded, implemented and evaluated?
  • What steps can countries take to expedite regulatory review of PrEP?
  • Are we adequately funding the HIV prevention research pipeline to ensure next generation prevention options are available as soon as possible?
  • How do we continue to drive progress on new prevention tools without losing focus on other proven methods, like condoms, behaviour change programmes and peer-to-peer interventions?
  • How can human rights approaches remain the key principle of HIV work?
  • How can we move beyond fighting legislation to building environments that support the rights of all, including sex workers, men who have sex with men, transgender men and women and people who use drugs?
  • How can the lessons of HIV be used to build a lasting legacy of social justice?
  • How do we make sure there is continued support for the robust basic science needed to find a cure and a vaccine?
  • How can researchers and private industry better collaborate to share knowledge and expedite the search for a cure and a vaccine?
  • How are we promoting and sustaining careers for the next generation of researchers and ensuring young researchers have a place in the future of HIV science? 
  • Where is our road map for ending the epidemic among all women and girls, including adolescents and those who are sex workers, transgender and/or who use drugs?
  • How can we build on the promising findings of the recent vaginal ring trials to ensure women have access to additional female-controlled prevention options?
  • How do we meaningfully address some of the gender norms that place women and girls at increased risk of HIV?
  • How can we accelerate the development of the next generation of paediatric formulations for HIV treatment?
  • What is needed to incentivize industry and research institutions to develop high-quality screening tools and treatment options for children?
  • How do we ensure that new technologies are affordable and rapidly reach all children living with HIV?
  • How can HIV treatment expansion efforts be more strategically positioned to reach men and boys?
  • How can we develop and implement adolescent-friendly services that more directly reach adolescent males – both HIV positive and negative?
  • How can men and boys become agents of social change?
  • How can access across the HIV cascade for key populations (men who have sex with men, transgender people, sex workers and people who inject drugs) be improved?
  • How should the meaningful engagement of key populations in policies and services that affect their lives be advanced in the health sector and across the workplace?
  • Are we doing enough to reach adolescent key populations?
  • How can we most effectively communicate the value of civil society and advocacy in the fight against AIDS? Which agencies, philanthropies and other institutions will commit to increase funding for civil society?
  • How can we ensure that the GIPA (Greater Involvement of People Living with HIV) Principle is actively put into action by all agencies involved in the AIDS response?
  • How can community-led services increasingly become part of the HIV tapestry?

Your answers to the big questions